The global biopharmaceutical CMO & CRO (contract manufacturing & research) market is expected to reach USD 37.8 billion by 2025, according to this new report. Healthy outlook of biopharmaceuticals and consequent growth in biopharmaceutical pipelines has resulted into lack of adequate capacity and budget constraints.

A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing.Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is co-funded by Innovate UK.

Schmolz + Bickenbach Announces $49.96 Million Investment in Swiss Steel

This latest report "Global Sickle Cell Market: Industry Analysis & Outlook (2020-2030)" provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, and Europe along with the global market.

Schmolz + Bickenbach Announces $49.96 Million Investment in Swiss Steel

MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it has closed enrollment in the Company's Plantar Fasciitis Investigational New Drug (IND) Phase 2B trial in accordance with an amendment filed with the Food and Drug Administration (FDA).

Novartis is buying U.S.based Selexys Pharmaceuticals in a deal worth up to $665 million, the Swiss drugmaker said on Monday, expanding its pipeline of medicines to combat blood diseases.Novartis, which last week was reported to be in talks with U.S. generics maker Amneal.

MarketOptimizer.org adds new report "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape

Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical company, announced on July 23 that the company will be investing US$30 million in Remiges BioPharma Fund (hereinafter "Remiges Fund"), a newly formed biotech venture capital fund.

NLMK Group to Build New Reheating Furnace at NLMK Pennsylvania

Morphogenesis Inc., the biotechnology firm developing ImmuneFx™, a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri.